BIOMAT Database Logo BIOMAT Database Logo

A double-blind, placebo-controlled study of alpidem, a novel anxiolytic of imidazopyridine structure, in chronically anxious patients. 1989

M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Department of Psychiatry, Faculty of Medicine, L'Aquila University, Italy.

In this double-blind study alpidem, a new imidazopyridine anxiolytic drug, was compared with placebo to assess its efficacy and safety in severely anxious patients at the fixed dose of 150 mg/day (50 mg t.i.d.) for 3 weeks. Fifty-nine patients with a score of at least 18 on the Hamilton Rating Scale for Anxiety (HRSA) entered the trial after a 3- to 7-day placebo run-in period. Symptom improvement was evaluated with the HRSA, the State and Trait Anxiety Inventory (STAI-1 and STAI-2), a Visual Analogue Scale (VAS) and the Clinical Global Impression (CGI). Alpidem was more effective than placebo in improving mean HRSA (total score and factorial scores for somatic and psychic anxiety), STAI-1 and STAI-2 and VAS scores. The efficacy index of the CGI was better for alpidem than for placebo. Side effects were negligible in both groups. Alpidem appears to be a new interesting anxiolytic drug devoid of significant sedative effects on mental functions.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009771 Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. Anankastic Personality,Neurosis, Obsessive-Compulsive,Anankastic Personalities,Disorder, Obsessive-Compulsive,Disorders, Obsessive-Compulsive,Neuroses, Obsessive-Compulsive,Neurosis, Obsessive Compulsive,Obsessive Compulsive Disorder,Obsessive-Compulsive Disorders,Obsessive-Compulsive Neuroses,Obsessive-Compulsive Neurosis,Personalities, Anankastic,Personality, Anankastic
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003291 Conversion Disorder A disorder whose predominant feature is a loss or alteration in physical functioning that suggests a physical disorder but that is actually a direct expression of a psychological conflict or need. Astasia-Abasia,Conversion Neurosis,Functional Movement Disorder,Functional Neurological Disorder,Hysteria, Conversion,Conversion Reaction,Astasia Abasia,Conversion Disorders,Conversion Hysteria,Conversion Neuroses,Disorder, Functional Movement,Disorder, Functional Neurological,Functional Movement Disorders,Functional Neurological Disorders,Movement Disorder, Functional,Movement Disorders, Functional,Neurological Disorder, Functional,Neurological Disorders, Functional,Neuroses, Conversion,Neurosis, Conversion
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Alpidem, a novel anxiolytic drug. A double-blind, placebo-controlled study in anxious outpatients.
February 1989, Clinical neuropharmacology,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Effects of alpidem in anxious elderly outpatients: a double-blind, placebo-controlled trial.
December 1992, Clinical neuropharmacology,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Discriminative stimulus effects of alpidem, a new imidazopyridine anxiolytic.
January 1994, Psychopharmacology,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Pilot study of alpidem, a novel imidazopyridine compound, in anxiety.
January 1988, Psychopharmacology bulletin,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
[Anxiolytic efficacy and tolerance of tetrabamate in anxious patients abusing alcohol. Multicenter double-blind versus placebo study].
January 1986, L'Encephale,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Melperone in low doses in anxious neurotic patients. A double-blind placebo-controlled clinical study.
January 1984, Neuropsychobiology,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Evaluation of levetiracetam as a pre-operative anxiolytic: A randomized, double-blind, placebo-controlled study.
August 2015, Indian journal of anaesthesia,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Anxiolytic effect of rescue remedy for psychiatric patients: a double-blind, placebo-controlled, randomized trial.
October 2006, Journal of clinical psychopharmacology,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
Parecoxib Possesses Anxiolytic Properties in Patients Undergoing Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Clinical Study.
June 2016, Pain and therapy,
M Casacchia, and A Farolfi, and P Priore, and G Magni, and P Stratta, and B Cesana, and A Rossi
A double blind, placebo-controlled trial of demeclocycline treatment of polydipsia-hyponatremia in chronically psychotic patients.
August 1991, Biological psychiatry,
Copied contents to your clipboard!